PALOMA-2: Palbociclib + Letrozole — Mobile Quick Reference

Save for clinic

📖 Full analysis: Desktop version — complete efficacy tables, safety detail, subgroup data, and clinical implications

🎯 Clinical Bottom Line

PALOMA-2 confirmed that adding palbociclib to letrozole as first-line therapy for postmenopausal women with ER-positive, HER2-negative advanced breast cancer extends progression-free survival by more than ten months compared with letrozole alone. The benefit was consistent across all subgroups. This trial established palbociclib plus letrozole as a first-line standard of care and led to full FDA approval.

Key Result: Investigator-assessed PFS — 24.8 vs 14.5 months, HR 0.58 (95% CI 0.46–0.72; P<0.001)

Safety Signal: Grade 3/4 neutropenia in 66.4% — but febrile neutropenia only 1.8%. No treatment-related deaths in the palbociclib arm. Managed with 3-weeks-on/1-week-off dosing and dose reductions (36.0%).

✅ Patient Eligibility

Must Have:

• ER-positive, HER2-negative advanced breast cancer
• Postmenopausal
• No prior systemic therapy for advanced disease
• ECOG PS 0–2
• Measurable disease (RECIST v1.1) or bone-only disease

Cannot Have:

• Prior nonsteroidal AI with recurrence during or within 12 months of therapy
• Advanced, symptomatic visceral spread at risk for life-threatening complications

💊 Dosing Quick Guide

Experimental Regimen

Palbociclib: 125 mg PO once daily, days 1–21 of 28-day cycle (3 weeks on / 1 week off) Letrozole: 2.5 mg PO once daily, continuous Cycle: 28 days Duration: Until progression, unacceptable toxicity, or withdrawal

Control Regimen

Placebo: Matched, same schedule as palbociclib Letrozole: 2.5 mg PO once daily, continuous

Key Dose Modifications [2]

Per FDA prescribing information — not trial protocol - Dose reduction levels: 125 mg → 100 mg → 75 mg once daily; discontinue if further reduction required [2] - Hold for ANC <1,000/mm³ or grade ≥3 non-hematologic toxicity; resume at same or next lower dose per recovery criteria [2] - Monitor CBC prior to start, day 15 of first 2 cycles, then before each cycle [2]

Mechanism: Palbociclib is a selective, reversible oral CDK4/6 inhibitor that blocks Rb phosphorylation and G1-to-S cell cycle progression. The 3-weeks-on/1-week-off schedule allows hematologic recovery between cycles [2].

⚠️ Safety Snapshot

Key safety metrics:

• Treatment-related deaths: 0 palbociclib; 1 placebo
• Discontinuations due to AE: 9.7% vs 5.9%
• Dose reductions: 36.0% vs 1.4%
• Serious AEs: 19.6% vs 12.6%

📊 Key Numbers

Median follow-up: 23 months

🔬 Key Comparator Context

Cross-trial comparisons are limited by differences in populations, designs, and endpoints.

🔍 Subgroups to Watch

Visceral disease: HR 0.63 (95% CI 0.47–0.85) — benefit maintained in visceral disease Nonvisceral disease: HR 0.50 (95% CI 0.36–0.70) — numerically stronger in nonvisceral Bone-only disease: HR 0.36 (95% CI 0.22–0.59) — particularly pronounced benefit DFI ≤12 months: HR 0.50 (95% CI 0.33–0.76) — strong benefit in early relapse Newly metastatic: HR 0.67 (95% CI 0.46–0.99) — benefit extends to de novo metastatic Prior hormonal therapy: HR 0.53 (95% CI 0.40–0.70) — robust benefit in pretreated patients Lobular carcinoma: HR 0.46 (95% CI 0.26–0.78) — pronounced benefit in lobular histology

Subgroup analyses were prespecified but not powered for formal comparisons. Results are hypothesis-generating.

📋 Regulatory Status

⚠️ Verify current regulatory status before prescribing.

NCCN: CDK4/6 inhibitor + AI is a preferred first-line regimen for HR+/HER2− MBC — Category 1 [3]

⚡ Grey Zones

• OS data immature at this analysis — survival benefit not established at publication
• Premenopausal women excluded — applicability with ovarian suppression not addressed by this trial
• No molecular biomarker beyond ER+/HER2− to identify patients with maximal or minimal benefit
• Post-progression therapy and sequencing (including next CDK4/6i) not reported
• Visceral crisis excluded — cannot replace chemotherapy in life-threatening visceral disease

📖 Full Analysis

Read the complete desktop article with full efficacy tables, safety detail, subgroup data, comparator trials, and clinical implications at kill-cancer.com

About the Author

Andrew Stevenson is the founder and systems architect of kill-cancer.com. He holds 17 Google technical certifications in data systems, automation, and applied AI — the engineering foundation behind the extraction and verification pipeline that produces every article on this platform. Every number traces to its source publication. Zero calculation. Zero editorializing. Zero hallucination. Five siblings lost to cancer built the urgency. The engineering builds the trust.

📧 andrew@kill-cancer.com 🌐 kill-cancer.com 💬 kill-cancer.com/forum

For healthcare professionals only. Not medical advice. Trial results are presented as reported in the source publication. Updated data, label changes, or guideline revisions published after the source article may alter clinical applicability. Consult FDA labeling, NCCN guidelines, and institutional protocols.

References

1. Finn RS, Martin M, Rugo HS, et al. Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J Med. 2016;375(20):1925-1936. doi:10.1056/NEJMoa1607303
2. Ibrance (palbociclib) prescribing information. U.S. Food and Drug Administration. Accessed March 2026.
3. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 1.2026. Accessed March 2026.
4. Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. N Engl J Med. 2016;375(18):1738-1748. doi:10.1056/NEJMoa1609709
5. Goetz MP, Toi M, Campone M, et al. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. J Clin Oncol. 2017;35(32):3638-3646. doi:10.1200/JCO.2017.75.6155